IMRX - Immuneering Corporation

-

$undefined

N/A

(N/A)

Immuneering Corporation NasdaqGM:IMRX Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Location: 245 Main Street, Cambridge, MA, 02142, United States | Website: https://immuneering.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

20.04M

Cash

35.87M

Avg Qtr Burn

-13.4M

Short % of Float

3.17%

Insider Ownership

24.00%

Institutional Own.

12.58%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
IMM-1-104 Details
Solid tumor/s, Cancer, Pancreatic cancer

Phase 2a

Data readout

IMM-1-104 + G12C inhibitor Details
Cancer, Non-small cell lung carcinoma

Phase 2a

Initiation

Phase 2a

Initiation

Phase 2a

Initiation

IMM-1-104 + Libtayo Details
Cancer, Non-small cell lung carcinoma

Phase 2a

Initiation

IMM-6-415 Details
Solid tumor/s

Phase 1/2

Data readout